News
-
-
-
PRESS RELEASE
Intellipharmaceutics International Inc. Announces Stock Option Grant
Intellipharmaceutics International Inc. issued 1,910,000 common share purchase options to certain eligible individuals under the stock option plan. The options vest over a period of 2 years and expire on February 5, 2034 -
PRESS RELEASE
Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange
Intellipharmaceutics International Inc., a pharmaceutical company, has received conditional approval to list its common shares on the TSX Venture Exchange as a Tier 2 Life Science Issuer. The company's management is working to meet the listing conditions, with expectations for a seamless transition from the Toronto Stock Exchange. Intellipharmaceutics specializes in the research, development, and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix ™ technology offers a multidimensional controlled-release drug delivery platform with various product candidates in the development pipeline. The company has also issued cautionary statements regarding forward-looking information. For further details, refer to the press release. -
-
PRESS RELEASE
Intellipharmaceutics Reports Director Election Results
-
